Molecular Analysis of p21 Promoter Activity Isolated from Squamous Carcinoma Cell Lines of the Head and Neck under the Influence of 1,25(OH) 2 Vitamin D3 and its Analogs

Acta Oto-Laryngologica

Volumn 124, Issue 1, 2004, Pages 90-96

  Hager, Gudrun ^a   Kornfehl, Johannes ^a   Knerer, Birgit ^a   Weigel, Guenter ^a   Formanek, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cell cycle arrest; Gene regulation; Transcription factor

Indexed keywords

20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; 20 EPICALCITRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; GREEN FLUORESCENT PROTEIN; PROTEIN P21; PROTEIN P27; SEOCALCITOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; GENE EXPRESSION; GENE TARGETING; GENE VECTOR; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; KERATINOCYTE; MITOSIS INHIBITION; MOLECULAR DYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; LARYNGEAL NEOPLASMS; LUMINESCENT PROTEINS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS P21(RAS); TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0842287309     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480310015353     Document Type: Article

References (25)

1. McElwain MC, Modzelewski RA, Yu WD, Russell DM, Johnson CS. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol 1997; 18: 293-8.
2. 3 analogue EB1089. Eur J Cancer 1996; 32A: 842-8.
3. 3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805-10.
4. Brown AJ. Therapeutic uses of vitamin D analoga. Am J Kidney Dis 2001; 38: S3-S19.
5. 3) on head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol 1996; 253: 341-4.
6. 3 induces elevated expression of the cell cycle-regulating genes p21 and p27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 2001; 121: 103-9.
7. 3 are mediated exclusively through the genomic signalling pathway. Endocrinol 1996; 137: 1554-61.
8. Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (Spp-1 or osteopontin) gene expression. Proc Natl Acad Sci U S A 1990; 87: 9995-9.
9. 3. Proc Natl Acad Sci U S A 1990; 87: 369-73.
10. Ozono K, Liao J, Kerner SA, Scott RA, Pike JW. The vitamin D-responsive element in the human osteocalcin gene. J Biol Chem 1990; 265: 21881-8.
11. Chen KS, DeLuca HF. Cloning of the human 1α,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochem Biophys Acta 1995; 1263: 1-9.
12. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142-53.
13. 3 receptor in the absence of the retinoid receptor. Mol Endocrinol 1994; 8: 265-73.
14. Nishikawa J, Kitaura M, Matsumoto M, Imagawa M, Nishihara T. Difference and similarity of DNA sequence recognized by VDR homodimer and VDR/RXR heterodimer. Nucl Acids Res 1994; 22: 2902-7.
15. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
16. 2 leads to differentiation of p53-deficient MG-63 osteosarcoma cells. Hum Pathol 2001; 32: 410-6.
17. Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
18. 3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol Endocrinol 2001; 15: 1127-39.
19. Waf1/Cip1 in vitro and in vivo. Cancer Res 1999; 59: 2644-9.
20. Kip1. Blood 1997; 93: 2225-33.
21. Sherr CJ. Cancer cell cycles revisited. Cancer Res 2000; 60: 3689-95.
22. Izzo JG, Papadimitrakopoulou VA, Li XQ, et al. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 1998; 17: 2313-22.
23. Somers KD, Merrick AM, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res 1992; 52: 5997-6000.
24. Qin LF, Ng IO. Exogenous expression of p21 (WAF1/ CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 2001; 172: 7-15.
25. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997; 57: 3759-64.